These findings were confirmed in another recent study showing that the percent of TP53-positive tumor cell nuclei by immunohistochemistry, a reliable measure of the presence of TP53 abnormalities in tumor cells, associates with shorter time to biochemical relapse and higher incidence of metastatic relapse and of prostate cancer-related mortality [300]. The gene discussed is TP53; the disease is neoplasm.